Copy/Paste the key inputs from the product brochure, per guidance from Marketing.
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous urticaria. However, both drug classes have serious side effects, and many patients still struggle to control their lesions. As a result, the approval of Xolair has been welcomed by physicians and patients. Clinical trials for additional biological therapies are underway, capturing urticaria disease data using an array of clinical scoring systems. With only one biological drug currently approved, the most important factors for driving prescribing decisions remain unknown, and many of the unmet needs in this market remain unfulfilled.
- What is the physician perspective on steroids and antihistamines for chronic urticaria? How frequently are these therapies prescribed?
- How do allergists and dermatologists diagnose and treat chronic urticaria, and how does treatment differ between specialists? Are inducible and spontaneous urticaria treated similarly, or is the treatment algorithm distinct?
- Which therapies are expected to have the biggest impact on the chronic urticaria market forecast? Will emerging therapies shift the treatment algorithm, or will biologics remain later-line treatments?
- How does Xolair (Novartis / Genentech), approved for chronic idiopathic urticaria in the United States, perform, and how will emerging biologics compare? How does its performance compare with that of frequently prescribed conventional therapies, including steroids and antihistamines?
Geographies: United States, EU5, Japan.
Primary research: 18 country-specific interviews with thought-leading allergists and dermatologists supported by survey data collected for this and other DRG research.
Epidemiology: Number of chronic urticaria patients by country, including diagnosed and drug-treated patients
Forecast: 10-year, annualized, drug-level sales and patient share of key chronic urticaria therapies through 2029, segmented by brands/generics.
Emerging therapies: Phase III / PR: 3 drugs; Phase II: 3 drugs; coverage of select preclinical and Phase I products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
- Urticaria - Landscape & Forecast - Disease Landscape And Forecast
Author(s): Kristine Mackin, PhD; Devashri Mukherjee, MPH
Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.
She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.
Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.
Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.